Llusern Scientific is delighted to announce that David Browning has joined as non-executive Chairman. David applies 40 years life-science experience translating scientific discoveries to deliver global market impact.

His wide-ranging experience includes roles with NHS Clinical Biochemisty, Amersham International, J&J, Philips, MediCity/BioCity (now Pioneer Group), Oxford University and UK and international start-ups and spin-outs.

David currently sits as a Board member or Advisor for a number of organisations including Institute for Cancer Research, Precision Health Technology Accelerator, Clinical Immunology Service, OBN and digital medtech companies.

The Lodestar DX analyser and testing system is registered with the European Patent Office (European Patent Application no: 22732302.9) and the US Patent and Trademark Office (no.18/558,490).